Joshua MBA - Predictive Oncology Interim Officer
| POAI Stock | USD 0.75 0.03 4.17% |
Executive
Joshua MBA is Interim Officer of Predictive Oncology
| Age | 51 |
| Address | 91 43rd Street, Pittsburgh, PA, United States, 15201 |
| Phone | (412) 432-1500 |
| Web | https://www.predictive-oncology.com |
Predictive Oncology Management Efficiency
The company has return on total asset (ROA) of (0.558) % which means that it has lost $0.558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4936) %, meaning that it created substantial loss on money invested by shareholders. Predictive Oncology's management efficiency ratios could be used to measure how well Predictive Oncology manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.04. The current Return On Capital Employed is estimated to decrease to -1.4. As of now, Predictive Oncology's Non Currrent Assets Other are decreasing as compared to previous years. The Predictive Oncology's current Net Tangible Assets is estimated to increase to about 26 M, while Total Assets are projected to decrease to under 9.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ekene Ofodile | Innovative Eyewear | N/A | |
| Klint Rose | Bionano Genomics | N/A | |
| Brian Miller | Intuitive Surgical | N/A | |
| Maggie McGowan | Nyxoah | N/A | |
| Guy Judkowski | Stereotaxis | N/A | |
| Marshall Mohr | Intuitive Surgical | 68 | |
| Sheila MBA | Bionano Genomics | N/A | |
| Remi Renard | Nyxoah | N/A | |
| Konrad Dabrowski | Innovative Eyewear | 41 | |
| Francis Kim | Nyxoah | 57 | |
| Patricia Wadors | Intuitive Surgical | 59 | |
| Paul Goode | GlucoTrack | 56 | |
| Ben Scheu | Sharps Technology | N/A | |
| Jonathan JD | Bionano Genomics | 49 | |
| James Cardwell | GlucoTrack | 63 | |
| Robert DeSantis | Intuitive Surgical | 58 | |
| Jeyakumar Subbaroyan | Nyxoah | N/A | |
| Linda Cooper | Daxor | N/A | |
| David DeMartino | Nyxoah | N/A | |
| Andy Molnar | Milestone Scientific | 62 | |
| Mark Tapsak | GlucoTrack | 55 | |
Management Performance
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.56 |
Predictive Oncology Leadership Team
Elected by the shareholders, the Predictive Oncology's board of directors comprises two types of representatives: Predictive Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Predictive. The board's role is to monitor Predictive Oncology's management team and ensure that shareholders' interests are well served. Predictive Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Predictive Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua MBA, Interim Officer | ||
| BS BSc, VP RD | ||
| Pamela MBA, Chief Officer | ||
| MD FCAP, Senior Director | ||
| Raymond Vennare, CEO Chairman | ||
| DSc OD, VP Operations | ||
| Julia Kirshner, Chief Officer | ||
| Robert Myers, CFO Sec | ||
| Robert MBA, CFO Sec | ||
| Theresa Ferguson, Director Marketing |
Predictive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Predictive Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.56 | ||||
| Operating Margin | (11.44) % | ||||
| Current Valuation | 4.12 M | ||||
| Shares Outstanding | 6.67 M | ||||
| Shares Owned By Insiders | 2.16 % | ||||
| Shares Owned By Institutions | 4.01 % | ||||
| Number Of Shares Shorted | 148.96 K | ||||
| Price To Book | 2.44 X | ||||
| Price To Sales | 2.75 X |
Currently Active Assets on Macroaxis
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.416 | Quarterly Revenue Growth (0.43) | Return On Assets (0.56) | Return On Equity (1.49) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.